Charles Schwab Investment Management Inc. Raises Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Charles Schwab Investment Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 1.7% during the 1st quarter, owning over 1 million shares valued at approximately $13.19 million.
• Institutional investors currently own 62.61% of Arrowhead Pharmaceuticals, with significant stakes increases reported by Vanguard Group, Northern Trust, and Millennium Management.
• Wall Street analysts have mixed ratings for Arrowhead, with an average target price of $43.14 but varying recommendations that include "strong buy," "buy," and "hold" ratings.

Charles Schwab Investment Management Inc. increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 1.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,035,290 shares of the biotechnology company's stock after buying an additional 17,570 shares during the period. Charles Schwab Investment Management Inc. owned 0.75% of Arrowhead Pharmaceuticals worth $13,190,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Exchange Traded Concepts LLC raised its stake in Arrowhead Pharmaceuticals by 31.8% in the first quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company's stock worth $627,000 after buying an additional 11,879 shares in the last quarter. Raymond James Financial Inc. bought a new position in Arrowhead Pharmaceuticals in the fourth quarter worth about $651,000. GAMMA Investing LLC raised its stake in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,628 shares in the last quarter. New York State Teachers Retirement System raised its stake in Arrowhead Pharmaceuticals by 6.9% in the first quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company's stock worth $1,890,000 after buying an additional 9,593 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in Arrowhead Pharmaceuticals by 117.8% in the first quarter. Principal Financial Group Inc. now owns 629,075 shares of the biotechnology company's stock worth $8,014,000 after buying an additional 340,191 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 9,389 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $20.00, for a total transaction of $187,780.00. Following the sale, the insider owned 262,122 shares in the company, valued at $5,242,440. This represents a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ:ARWR traded down $0.31 during trading on Friday, reaching $22.03. 2,388,669 shares of the stock traded hands, compared to its average volume of 2,433,496. The stock has a 50-day moving average of $17.71 and a two-hundred day moving average of $16.02. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $27.34. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The stock has a market cap of $3.05 billion, a P/E ratio of -17.21 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to analysts' expectations of $29.01 million. During the same quarter last year, the firm posted ($1.38) EPS. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Royal Bank Of Canada decreased their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Finally, Citigroup decreased their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.